Riqing Huang

State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.

Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.

Journal: Cancer communications (London, England)

Published: December 13, 2025

Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study.

Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study.

Journal: The oncologist

Published: April 16, 2025

Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial.

Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial.

Journal: Journal for immunotherapy of cancer

Published: March 24, 2025

Osteosclerotic changes on computed tomography predict disease progression and poor survival in prostate cancer with osteoblastic metastases.

Osteosclerotic changes on computed tomography predict disease progression and poor survival in prostate cancer with osteoblastic metastases.

Journal: International journal of surgery (London, England)

Published: March 23, 2025

Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study.

Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study.

Journal: Journal of cancer research and clinical oncology

Published: March 20, 2025

Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.

Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.

Journal: The New England journal of medicine

Published: February 19, 2025

Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)： A phase III crossover trial.

Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)： A phase III crossover trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 07, 2025

Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer.

Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer.

Journal: Journal of translational medicine

Published: November 04, 2024

Efficacy and safety of modified bleomycin administration with EP chemotherapy in adult male patients with germ cell tumors: a retrospective study.

Efficacy and safety of modified bleomycin administration with EP chemotherapy in adult male patients with germ cell tumors: a retrospective study.

Journal: Cancer cell international

Published: October 21, 2024

RNF135 promotes the stemness of breast cancer cells by ubiquitinating and degrading DDX58.

RNF135 promotes the stemness of breast cancer cells by ubiquitinating and degrading DDX58.

Journal: Translational oncology

Published: September 30, 2024

Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.

Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.

Journal: BJU international

Published: November 27, 2023

Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance.

Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance.

Journal: The oncologist

Published: November 15, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026